Human herpesvirus type 6 reactivation after haematopoietic stem cell transplantation.
Human herpesvirus type 6 (HHV6) is known to reactivate after hematopoetic stem cell transplantation (HSCT) and has been suggested to be associated with increased mortality and severe clinical manifestations, including graft versus host disease (GvHD). The exact etiological role of HHV6 reactivation in increased morbidity and mortality after HSCT remains unclear. This review will focus on the current available evidence of HHV6 reactivation after HSCT and its immuno-modulatory capacities, with particular emphasis on the severe complication GvHD. At present, no effective specific antiviral treatment for HHV6 reactivation has been identified. The currently available antiviral agents are outlined, as well as possible future strategies for the treatment of HHV6 reactivation. Non-toxic, specific treatment or prevention of HHV6 reactivation might improve the safety and efficacy of the HSCT procedure.
de Pagter
P J
PJ
Department of Immunology and BMT, University Medical Center Utrecht, Utrecht, The Netherlands. p.j.depagter@umcutrecht.nl
Schuurman
Rob
R
Meijer
Ellen
E
van Baarle
Debbie
D
Sanders
E A M
EA
Boelens
J J
JJ
D000998:Antiviral Agents / Q000627:therapeutic use; D006086:Graft vs Host Disease; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D052163:Human papillomavirus 6 / Q000502:physiology*; D006801:Humans; D030361:Papillomavirus Infections / Q000150:complications / Q000188:drug therapy / Q000276:immunology; D017464:Receptors, Complement 3d
D000998:Antiviral Agents; D017464:Receptors, Complement 3d